{"id":15131,"date":"2021-07-22T12:59:48","date_gmt":"2021-07-22T12:59:48","guid":{"rendered":"https:\/\/clinlabint.com\/?p=15131"},"modified":"2021-07-22T12:59:48","modified_gmt":"2021-07-22T12:59:48","slug":"avactas-affidx-sars-cov-2-antigen-lateral-flow-test-detects-delta-variant-with-high-sensitivity","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/avactas-affidx-sars-cov-2-antigen-lateral-flow-test-detects-delta-variant-with-high-sensitivity\/","title":{"rendered":"Avacta\u2019s AffiDX SARS-CoV-2 Antigen Lateral Flow Test detects Delta variant with high sensitivity"},"content":{"rendered":"<p><img decoding=\"async\" class=\"alignnone  wp-image-15132\" src=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/avacta_web-300x205.jpg\" alt=\"Avacta AffiDX SARS-CoV-2 Antigen Lateral Flow Test\" width=\"520\" height=\"355\" title=\"\" srcset=\"https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/avacta_web-300x205.jpg 300w, https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/avacta_web-1030x705.jpg 1030w, https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/avacta_web-768x526.jpg 768w, https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/avacta_web-705x483.jpg 705w, https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2021\/07\/avacta_web.jpg 1408w\" sizes=\"(max-width: 520px) 100vw, 520px\" \/><\/p>\n<p>Avacta Group, the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer\u00a0and pre|CISION platforms, says a recent study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples.<\/p>\n<p>Lateral flow antigen tests are intended to provide a cost effective and rapid means of identifying individuals with a high viral load that means they are more likely to infect others. The clinical data for Avacta\u2019s AffiDX SARS-CoV-2 antigen lateral flow test demonstrated 100% sensitivity for identifying infectious individuals with viral loads measured by PCR of Ct&lt;27, which is considered infectious.<\/p>\n<p>The AffiDX SARS-CoV-2 antigen lateral flow test has been evaluated with a small number of patient samples confirmed to be Delta variant positive and, for a Ct&lt;29, the test was shown to correctly identify all the positive cases.<\/p>\n<p>The AffiDX SARS-CoV-2 antigen lateral flow test is CE marked for professional use in the UK and EU. The Company has recently appointed the first distributor for the test, Calibre Scientific, and is progressing multiple commercial opportunities with other distributors and professional end users in Europe and the UK.<\/p>\n<p>Dr Alastair Smith, Chief Executive Officer of Avacta Group, commented:\u00a0\u201cWe are delighted to report that the AffiDX SARS-CoV-2 antigen lateral flow test detects the Delta variant with very high sensitivity for patients with a Ct value of less than 29. This is a variant of the virus that is spreading rapidly on a global scale and therefore the ability of the test to detect this variant is paramount to our commercial roll-out.<\/p>\n<p>\u201cIn comparison with other lateral flow tests on the market, Avacta\u2019s rapid antigen test demonstrates better clinical performance. This is a further huge validation of the Affimer\u00a0reagent platform for use in in-vitro diagnostics.<\/p>\n<ul>\n<li>The AffiDX SARS-Cov-2 rapid antigen test is not currently available for sale in the United States.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Avacta Group, the developer of diagnostics and innovative cancer therapies based on its proprietary Affimer\u00a0and pre|CISION platforms, says a recent study has shown that the AffiDX antigen lateral flow test detects the Delta variant of the SARS-CoV-2 virus in clinical samples. Lateral flow antigen tests are intended to provide a cost effective and rapid means [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":15132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39],"tags":[],"class_list":["post-15131","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-product-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/15131"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=15131"}],"version-history":[{"count":2,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/15131\/revisions"}],"predecessor-version":[{"id":15134,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/15131\/revisions\/15134"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/15132"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=15131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=15131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=15131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}